Inhalation Sciences holds extraordinary shareholder meeting, approves TO4 warrant issue to lenders

• Inhalation Sciences Sweden AB held an extraordinary general meeting on Aug. 18, 2026.
• Shareholders endorsed the July 28, 2026 credit facility agreement with Tellus Equity, JEQ Capital, Thalor Capital; execution not confirmed.
• A directed issue of up to 8,800,000 TO 4 warrants to the lenders was ratified; issuance completion not confirmed.
• The board received authority to issue shares, warrants, convertibles with pre-emption rights before the next AGM; no issuance confirmed.
• A separate mandate for non-pre-emptive issuance was adopted, capped at 40% of outstanding shares at notice date; no transaction confirmed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhalation Sciences Sweden AB published the original content used to generate this news brief via Cision (Ref. ID: 202608180748BITN____UKPR__SV_20260818-BIT-8786-0) on August 18, 2026, and is solely responsible for the information contained therein.